# Kilimanjaro (NCT05259839)

> A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05259839
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AbbVie
- Conditions: Relapsed/Refractory Multiple Myeloma
- Interventions: Etentamig; Dexamethasone; Lenalidomide; Pomalidomide; Daratumumab
- Enrollment: 283
- Primary outcome: Number of Participants with Dose Limiting Toxicities (DLT) of Etentamig
- Primary outcome: Number of Participants with Adverse Events (AEs)

## Indexed commentary on Kilimanjaro so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 4
- YouTube: 1
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=kilimanjaro-nct05259839